Kadcyla(TDM-1) is less costly then current standard of care.
Kadcyla shows a significant increase in PFS over the SOC with far fewer side effects.Patients will want it right away.
Herceptin already had the black box label, so nothing new on that front.
From the overall response from the ASCO meeting the oncology doctors will be prescribing Kadcyla in a big way.
Roche will offer programs to patients unable to afford the drug that will enable them to receive it.
With over 8 million shares short, the clock is ticking.
Two presentations to the investment communities over the next 2 days.Check IMGN website for times and to access them.
Our platform having been validated by this FDA approval will now gain additional interest from the investment community. Data, from our partnered pipeline products, as well as our fully owned products, will be coming out this year, and we'll see more of these getting approval.